Literature DB >> 6984354

Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer.

R Samak, R Edelstein, L Israel.   

Abstract

Acute-phase reactant proteins reach abnormally high levels in patients with cancer, and correlate with the extent of disease. In this study, several acute-phase glycoproteins, and serum albumin as a control, were tested at different concentrations for their ability to modify the blastogenic response of lymphocytes from 30 normal donors to PHA and the chemotactic response of monocytes from 15 normal donors to casein. In high concentrations approximating those found in cancer patients, but not in normal concentrations, haptoglobin and fibrinogen inhibited both functions to different degrees. Orosomucoid inhibited only monocyte chemotaxis, while ceruloplasmin and alpha 1-antitrypsin affected neither function. Increasing concentrations of PHA did not overcome the blocking effect of haptoglobin and fibrinogen on blastogenesis, suggesting that PHA-protein interaction was not responsible for the effect observed. The three proteins that did not suppress blastogenesis individually did so strongly when combined. It is suggested that these glycoproteins, synthesized by the liver in response to an inflammatory stimulus, may act as 'non-specific blocking factors' protecting tumors against the host's immunological attack. This non-specific blocking activity of the acute-phase proteins may contribute to the 'immune escape' of the tumor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6984354     DOI: 10.1007/BF00200198

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  IMMUNE RESPONSE AND MITOSIS OF HUMAN PERIPHERAL BLOOD LYMPHOCYTES IN VITRO.

Authors:  K HIRSCHHORN; F BACH; R L KOLODNY; I L FIRSCHEIN; N HASHEM
Journal:  Science       Date:  1963-11-29       Impact factor: 47.728

2.  Interactions of alpha1-acid glycoprotein with the immune system. I. Purification and effects upon lymphocyte responsiveness.

Authors:  K M Chiu; R F Mortensen; A P Osmand; H Gewurz
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

3.  Monocyte function in cancer patients.

Authors:  J G McVie; E C Logan; A B Kay
Journal:  Eur J Cancer       Date:  1977 Apr-May       Impact factor: 9.162

4.  Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas.

Authors:  I Hellström; K E Hellström; H O Sjögren
Journal:  Cell Immunol       Date:  1970-05       Impact factor: 4.868

5.  Elevated serum Cu in Hodgkin's disease and inhibitory effects of ceruloplasmin on lymphocyte response in vitro.

Authors:  B Larsen; I Heron; E B Thorling
Journal:  Eur J Cancer       Date:  1980-03       Impact factor: 9.162

6.  Serum haptoglobin in patients with ovarian malignancies.

Authors:  W K Mueller; R Handschumacher; M E Wade
Journal:  Obstet Gynecol       Date:  1971-09       Impact factor: 7.661

7.  Plasma alpha-1-antitrypsin levels in early and late carcinoma of the cervix.

Authors:  A L Latner; G A Turner; M M Lamin
Journal:  Oncology       Date:  1976       Impact factor: 2.935

8.  Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity.

Authors:  A M Baskies; P B Chretien; J F Weiss; R W Makuch; R A Beveridge; W J Catalona; H E Spiegel
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

9.  In vivo and in vitro studies on nonspecific blocking factors of host origin in cancer patients. Role of plasma exchange as an immunotherapeutic modality.

Authors:  L Israël; R Edelstein
Journal:  Isr J Med Sci       Date:  1978-01

10.  Acute-phase reactant protein profiles: an aid to monitoring large bowel cancer by CEA and serum enzymes.

Authors:  A M Ward; E H Cooper; R Turner; J A Anderson; A M Neville
Journal:  Br J Cancer       Date:  1977-02       Impact factor: 7.640

View more
  14 in total

1.  Acute phase proteins and infectious complications after surgery for esophageal cancer.

Authors:  T Saito; A Kuwahara; K Shimoda; T Kinoshita; K Sato; M Miyahara; M Kobayashi
Journal:  Jpn J Surg       Date:  1991-11

2.  Haptoglobin groups in motor neuron disease.

Authors:  N Fröhlander; L Forsgren
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-03       Impact factor: 10.154

3.  Expression of haptoglobin-related protein and its potential role as a tumor antigen.

Authors:  F P Kuhajda; A I Katumuluwa; G R Pasternack
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 4.  Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms.

Authors:  G A Turner; M T Goodarzi; S Thompson
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

5.  Induction of suppressor cell activities in normal lymphocytes by sera from gastric cancer patients.

Authors:  T Toge; M Tanada; K Yajima; H Kohno; E Itagaki; T Hattori
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

6.  Haptoglobin dampens endotoxin-induced inflammatory effects both in vitro and in vivo.

Authors:  Mohamed S Arredouani; Ahmad Kasran; Jeroen A Vanoirbeek; Frank G Berger; Heinz Baumann; Jan L Ceuppens
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

7.  Alpha 1-acid glycoprotein expression in human leukocytes: possible correlation between alpha 1-acid glycoprotein and inflammatory cytokines in rheumatoid arthritis.

Authors:  T Nakamura; P G Board; K Matsushita; H Tanaka; T Matsuyama; T Matsuda
Journal:  Inflammation       Date:  1993-02       Impact factor: 4.092

8.  Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers.

Authors:  John A Sandoval; Katharyn E Turner; Derek J Hoelz; Frederick J Rescorla; Robert J Hickey; Linda H Malkas
Journal:  J Surg Res       Date:  2007-08-29       Impact factor: 2.192

9.  Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release.

Authors:  M Arredouani; P Matthijs; E Van Hoeyveld; A Kasran; H Baumann; J L Ceuppens; E Stevens
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

10.  Prognostic significance of serum alpha 1-acid glycoprotein in patients with glioblastoma multiforme: a preliminary communication.

Authors:  H Matsuura; S Nakazawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.